Optimizing anemia management in lower-risk myelodysplastic syndromes
Pinkal Desai, MD, MPH, Weill Cornell Medicine, New York, NY, discusses the evolving treatment landscape for lower-risk myelodysplastic syndromes (LR-MDS), highlighting the growing role of luspatercept, the place of erythropoiesis-stimulating agents, and emerging strategies to optimize anemia management and improve long-term patient outcomes. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
